Literature DB >> 19369624

Follicular lymphoma of the spleen: multiparameter analysis of 16 cases.

Matthew T Howard1, Scott Dufresne, Steven H Swerdlow, James R Cook.   

Abstract

Follicular lymphoma (FL) involving the spleen must be distinguished from reactive hyperplasia and from other lymphomas. A prior study reported that splenic FLs frequently lack BCL2 expression, further complicating diagnosis. We examined 16 cases of splenic FL, including 12 cases initially diagnosed at splenectomy. Two morphologic patterns were identified: one with architectural abnormalities (AA) and one with an extensive architectural preservation (AP) pattern. Newly diagnosed AP cases were associated with older age (P = .051) and grade 1 histologic features (P = .023). All cases displayed a CD10+/BCL2+ phenotype. Cytogenetics and FISH identified IGH/BCL2 or BCL6 translocations in all tested cases. Splenic FLs display phenotypic and cytogenetic findings similar to nodal FLs. However, splenic FLs frequently display an exclusively intrafollicular growth pattern resembling so-called in situ FL. Recognition of subtle FL with preserved architecture is important because patients may have overt FL at other sites or the FL may progress to overt nodal disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19369624     DOI: 10.1309/AJCPF9V8XRDYWTIR

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma.

Authors:  Armin G Jegalian; Franziska C Eberle; Svetlana D Pack; Mariya Mirvis; Mark Raffeld; Stefania Pittaluga; Elaine S Jaffe
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

2.  Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies.

Authors:  Raju K Pillai; Urvashi Surti; Steven H Swerdlow
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

3.  The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow.

Authors:  Sheren F Younes; Andrew H Beck; Robert S Ohgami; Izidore S Lossos; Ronald Levy; Roger A Warnke; Yasodha Natkunam
Journal:  Am J Clin Pathol       Date:  2011-05       Impact factor: 2.493

4.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to August 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

5.  Pathologic splenic rupture in a patient with follicular lymphoma.

Authors:  A P Dayama; R Kapoor; J Dass; G Singh; M Mahapatra; H P Pati
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-11-10       Impact factor: 2.576

Review 6.  Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma.

Authors:  Rami Abdulbaki; Parastou Tizro; Victor E Nava; Maria Gomes da Silva; João L Ascensão
Journal:  Curr Oncol       Date:  2021-11-18       Impact factor: 3.677

Review 7.  Follicular lymphoma: updates for pathologists.

Authors:  Mahsa Khanlari; Jennifer R Chapman
Journal:  J Pathol Transl Med       Date:  2021-12-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.